Law Firm News

---

Law Firm News

Firm Name

News Title

News

News Date

25383 matches |  22163-22169 displayed

1  3166 3167 3168 3169 3170  3627

---

Hamburg, Rubin, Mullin, Maxwell & Lupin, Attorneys At Law

BARRETT APPOINTED PASC HEARING COMMITTEE MEMBER
Attorney Steven B. Barrett, partner in the law firm of Hamburg, Rubin, Mullin, Maxwell & Lupin has recently been appointed as a Hearing Committee Member serving the Disciplinary Board of the Supreme Court of Pennsylvania. This three-year appointment took effect on July 1, 2006.

Barrett's practice is multi-faceted, covering such areas as complex commercial, personal injury and real estate litigation. With significant and notable jury verdicts, he is considered one of the premier trial attorneys in Southeastern Pennsylvania.

Hamburg, Rubin, Mullin, Maxwell & Lupin is a full service law firm with offices in Lansdale, Perkasie, Limerick and Allentown, Pennsylvania.

07-02-2006

---

Frommer Lawrence & Haug LLP

Washington DC Office
Frommer Lawrence & Haug LLP is pleased to announce the opening of its Washington DC office.

07-01-2006

---

Frommer Lawrence & Haug LLP

Michael F. Brockmeyer joins FLH as head of Antitrust Practice Group
Frommer Lawrence & Haug LLP is proud to welcome Michael F. Brockmeyer to our firm as Chairman of our Antitrust Practice Group.

07-01-2006

---

Frommer Lawrence & Haug LLP

Elizabeth Leff joins FLH as a partner in FLH's Washington DC office
Frommer Lawrence & Haug LLP is pleased to announce our new partner Elizabeth Leff in the Washington DC office.

07-01-2006

---

Jones Day, P.C.

Firm Tops M&A League Tables for 23rd Quarter In a Row
In league tables published this month, Jones Day ranked #1 for number of deals worldwide, a position it has held since the end of 2000.

Jones Day led all law firms in both of Thomson Financial’s league tables based on number of deals completed in the first half of 2006, with 279 completed transactions worldwide and 148 completed deals with U.S. targets.

In the Bloomberg league tables, which are based on announced transactions, Jones Day maintained its #1 position for number of deals, with 263 announced transactions worldwide and 180 announced deals in the U.S.

The Firm has held the #1 worldwide ranking for number of deals in both the Thomson and Bloomberg tables for 23 consecutive quarters.

Mergerstat, which publishes league tables based only on announced deals involving U.S. companies, ranked Jones Day #1 for number of deals. The Firm has held the #1 position for number of deals in the Mergerstat rankings for 13 successive quarters.

07-01-2006

---

Jones Day, P.C.

Jones Day Lawyers Publish Law Review Article Analyzing CAFA
The Tulane Law Review devoted its June 2006 issue to a symposium on class actions in the gulf south and beyond. The Review invited a federal judge and many leading scholars in class action law to contribute articles to the issue. Jones Day Of Counsel Robert Klonoff and Partner Mark Herrmann contributed "The Class Action Fairness Act: An Ill-Conceived Approach to Class Settlements" to the symposium issue. Their article appears at 80 Tulane Law Review 1695.

07-01-2006

---

Jones Day, P.C.

Health Law360: 10 Stand-Out Firms Win Industry's Confidence
For health care companies, lawsuits have always been a cost of doing business. But as the stakes get higher in cut-throat litigation, that cost could very well become the business itself.

Just ask Merck & Co. By some counts, the company is now facing more than 13,000 lawsuits across the country related to its Vioxx pain treatment. With three losses so far, including a jury award of $253 million, the brand-name drug maker is vowing to fight back each lawsuit one by one.

Or take Guidant Corp., the medical device maker recently acquired by Boston Scientific. In the past two years, the company has been sued more than 700 times for product liability, mostly due to its recall of 109,000 defibrillators.

Triggered by concern over drug safety, the number of product liability lawsuits brought against health care companies has reached a staggering level. Plaintiffs filed more than 17,000 product liability lawsuits related to prescription drugs in federal courts last year, according to a recent study by legal researcher Thomson West.

Indeed, product liability suits against drug makers now account for more than a third of all product liability filings in federal courts, outnumbering classic class action claims involving asbestos, tobacco and auto safety, the study found.

But product liability suits are just part of the legal onslaught facing the health care and life sciences industries. Patent challenges, long a thorn in the side for brand name drug makers, have become increasingly sophisticated and complex.

And costly, too. Last year, Medtronic Inc. was forced to pay out the largest settlement in history in a patent infringement suit when the besieged company agreed to a write a colossal check for $1.35 billion to end a lawsuit filed by a Los Angeles surgeon.

Adding insult to injury, patent challenges are increasingly coupled with antitrust claims, making cases even harder to litigate. This spring, the states of Michigan, Maryland, New York and Wisconsin negotiated a 49-state antitrust settlement to recover $14 million from GlaxoSmithKline after allegations that the company had forced government health plans to pay inflated prices for Paxil by blocking generic versions of the drug.

And state attorneys general aren’t the only government officials breathing down drug makers’ necks. The Supreme Court recently offered a temporary respite from a landmark antitrust challenge by the Federal Trade Commission, but experts expect the agency to continue to go after “authorized-generic” deals it perceives as anti-competitive.

Just how bad are things? With its recent setbacks in the Vioxx litigation, Merck added $295 million to its reserves at the end of 2005 and has signaled that it will need at least $1 billion for legal fees. So far, the company has set aside at least $685 million to cover legal fees stemming from the suits.

Those fees, of course, promise a boom time for health care lawyers. And across the U.S., law firms are staffing up their health care and life sciences practices to meet the increasing demand for their services.

“People are really interested in health care because it affects you,” said Jan Levine, the chair of Dechert’s health law practice group. “Summer associates always want health care projects. Growth is going to happen, because when you come in, you know the industry already.”

Managing partner of Kaye Scholer, Barry Willner, said the pharmaceutical and biotechnology industries are a focus for his firm and are continually expanding.

These firms are being matched by increasingly sophisticated corporate counsel at the world’s top health care and life sciences companies. In a vivid example, Pfizer rented the ballroom at the Grand Plaza Hotel in New York for a “beauty contest” with 103 firms in attendance—and that was only the beginning of a nine-month search for the best health care lawyers.

We’ve done our own research, scouring court dockets to discover which national law firms have been retained by the largest companies in the health care industry in the past year.

Using WestLaw as our source, we analyzed dockets involving tens of thousands of lawsuits last year, including every single patent, antitrust, tort and securities lawsuit brought by or against the 250 largest publicly traded health care companies.

Armed with our quantitative data, we conducted additional research to select the best firms with a track record of success.

This list is in no way exhaustive but our choice of 10 of the top law firms that have stood out in the past year as leaders in defending the growing health-care industry.

07-01-2006

---

25383 matches |  22163-22169 displayed

1  3166 3167 3168 3169 3170  3627